The Food and Drug Administration (FDA) has approved the lower-cost version of Copaxone, the most-used drug for multiple sclerosis.
Teva Pharmaceutical Industries Ltd manufactures Copaxone. The generic drug, Glatopa, was developed collaboratively by Sandoz, a unit of Swiss drugmaker Novartis AG, and Momenta Pharmaceuticals Inc, for treating patients with relapsing forms of the chronic neurodegenerative disease.
Multiple Sclerosis
Multiple sclerosis can be a severely disabling autoimmune disease that affects the myelin or insulating layer of the nerve fibers and typically has remissions and relapses
Advertisement
However, the companies are still engaged with the patent litigation. Sreejit Mohan, spokesman of Sandoz, said the company would not comment on commercial launch plans.
Sources with Momenta said the 20 mg generic version of the blockbuster drug could be labeled 'substitutable', meaning prescriptions for Copaxone could be automatically switched to the generic.
Teva's U.S. sales of Copaxone totaled $3.1 billion in fiscal 2014. The company has been working to switch patients to a 40 mg formulation of the drug that still has patent protection.
Source: Medindia
Teva's U.S. sales of Copaxone totaled $3.1 billion in fiscal 2014. The company has been working to switch patients to a 40 mg formulation of the drug that still has patent protection.
Source: Medindia
Multiple Sclerosis Treatment and Modify
Multiple sclerosis is treated with drugs that modify the course of the disease, suppress immunity and relieve symptoms.
Advertisement
 Chemotherapy''Chemo'' means medicine or ''drug'', ''therapy'' means ''treatment''. Chemotherapy refers to the use of cytotoxic drugs in the treatment of cancer. | Advertisement
|
Advertisement
Latest Drug News
Addressing the unmet needs of Parkinson's Disease by providing disease-modifying therapies could bring about a major shift in the way that patients are treated.
Microrobots could swirl through a person's blood stream, search for targeted areas to treat for various ailments.
Supplementation with multivitamins is an inexpensive way for older adults to slow down memory loss.
Some people with an aggressive blood cancer called acute myeloid leukemia (AML) may soon have a new drug option called Ivosidenib that blocks the activity of IDH1 gene.
In case of cardiac failure where the ejection fraction is greater than 40%, sacubitril/valsartan can prove to be quite beneficial